Abstract
Objective To evaluate safety and efficacy of Itolizumab in hospitalized COVID-19 patients with PaO2/FiO2 ratio (PFR) ≤200 requiring oxygen therapy.
Design A multicentre, single-arm, Phase-4 study with a treatment period of 30-Days and an extended follow-up period of 90-Days.
Methods Hospitalized adult patients (n=300) with SARS-CoV-2 infection, with PFR ≤200; oxygen saturation ≤94% and ≥1 elevated inflammatory markers were included from 17 COVID-19-specific tertiary hospitals in India. Patients received Itolizumab infusion 1.6 mg/kg and were assessed for 1-month and then followed up to Day-90.
Results Day-30 post-treatment safety/efficacy results and Day-90 mortality results are presented. Primary outcome measures: incidence of severe acute infusion-related reactions (IRRs) (≥Grade-3) was 1.3% and mortality rate at 1-month was 6.7% (n=20/300). Key secondary analyses: Mortality rate at Day-90 was 8.0% (24/300). 91.7% patients came off the oxygen therapy within Day-30 of treatment. By Day-7, most patients had stable/improved SpO2 without increasing FiO2. Mean PFR improved by 50% by Day-7 (p<0.001) and the trend remained consistent till Day-30. Median time of recovery was 8 days. Cumulatively, at Day-30, 260(86.7%), 256(85.3%), 132(44.0%), 113(37.6%) and 32(10.7%) patients showed >1-point, >2-point, >3-point, >4-point and 5-point improvement on the modified COVID-19 8-point ordinal scale and worsening of symptoms by >1 point, >2 points and 3-points was seen in 26(8.7%), 20(6.7%) and 6(2.0%) patients, respectively. CRP, D-dimer, LDH, and serum ferritin levels significantly decreased (p≤0.01) compared with baseline. IL-6 and TNFα levels also decreased 48-hours post-infusion. Overall, 123 treatment-emergent adverse events (TEAEs) were reported in 63 patients, most being Grades 1-3. Most common TEAEs were IRRs and lymphopenia; most common serious TEAEs were septic shock, worsening of ARDS, and respiratory failure. No deaths were attributable to Itolizumab.
Conclusion Itolizumab shows no new safety concerns and suggests a mortality and recovery benefit at 1-month in hospitalized COVID-19 patients requiring oxygen therapy.
Trial registry number CTRI/2020/09/027941
Competing Interest Statement
Drs Raveendra KR, Chirag Rathod and Rahul Darnule received funding for the study and professional fees as Principal Investigators from Biocon Biologics Limited. All other authors are employees of Biocon Biologics Limited and may be eligible for stock and stock options.
Clinical Trial
CTRI/2020/09/027941
Funding Statement
This study was funded by Biocon Biologics Limited
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IECs of Govt. Medical College and Hospital, Nagpur; SRM Institutes for Medical Science, Chennai; T. N. Medical College & B.Y.L Nair Charitable Hospital, Mumbai; LMMFs Deenanath Mangeshkar Hospital and Research Center, Pune; GMERS Medical College & Hospital, Vadodara; Mahatma Gandhi Missions (MGIO Medical College & Hospital), Aurangabad; All India Institute of Medical Sciences (AIIMS), Raipur; Kasturba Hospital for Infectious Diseases, Mumbai; S. P. Medical College & AG of Hospitals, Bikaner; St. Georges Hospital, Mumbai; All India Institute Of Medical Sciences, Bhubaneswar; K R Hospital, Mysuru; Sawai Mansingh Medical College (SMS) Medical College, Jaipur; Narayana Hrudayalaya Limited, Bangalore; Victoria Hospital, Bangalore; SCB Medical College & Hospital, Cuttack; and ESIC Medical College and Hospital, Haryana gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The manuscript has been reformatted to include figures and tables in text instead of end of text.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
